Stefan Weber - Newron Pharmaceuticals CEO Director
| NWRN Stock | CHF 9.03 0.08 0.88% |
Insider
Stefan Weber is CEO Director of Newron Pharmaceuticals SpA
| Age | 58 |
| Phone | 39 02 610 3461 |
| Web | https://www.newron.com |
Newron Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1636) % which means that it has lost $0.1636 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.398) %, meaning that it generated substantial loss on money invested by shareholders. Newron Pharmaceuticals' management efficiency ratios could be used to measure how well Newron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Newron Pharmaceuticals SpA has accumulated 42.93 M in total debt with debt to equity ratio (D/E) of 0.7, which is about average as compared to similar companies. Newron Pharmaceuticals has a current ratio of 13.62, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Newron Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Newron Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Newron Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Newron to invest in growth at high rates of return. When we think about Newron Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Oliver Strub | Santhera Pharmaceuticals Holdin | 60 | |
| Thomas CFA | Evolva Holding SA | N/A | |
| Astrid Schafer | Evolva Holding SA | 50 | |
| Gnther Metz | Santhera Pharmaceuticals Holdin | 65 | |
| Shabir MD | Santhera Pharmaceuticals Holdin | N/A | |
| Luigi Longo | COSMO Pharmaceuticals SA | 44 | |
| Eva Kalias | Santhera Pharmaceuticals Holdin | N/A | |
| David Veitch | Basilea Pharmaceutica AG | 58 | |
| Adesh Kaul | Basilea Pharmaceutica AG | 49 | |
| Damian Heller | Basilea Pharmaceutica AG | 57 | |
| Fabienne Gschwind | Evolva Holding SA | 50 | |
| Hazel Winchester | COSMO Pharmaceuticals SA | 52 | |
| Niall Donnelly | COSMO Pharmaceuticals SA | 51 | |
| Alessandro LLM | COSMO Pharmaceuticals SA | 60 | |
| Ursula Eberhardt | Basilea Pharmaceutica AG | 61 | |
| Giulio Evangelisti | COSMO Pharmaceuticals SA | 53 | |
| Gerhard Lobmaier | Evolva Holding SA | 54 | |
| Oliver MBA | Evolva Holding SA | 54 | |
| Marc Schrader | Santhera Pharmaceuticals Holdin | N/A | |
| Philipp Frech | Evolva Holding SA | N/A | |
| Sarah HolmesKlotz | Santhera Pharmaceuticals Holdin | N/A | |
Management Performance
| Return On Equity | -8.4 | |||
| Return On Asset | -0.16 |
Newron Pharmaceuticals Leadership Team
Elected by the shareholders, the Newron Pharmaceuticals' board of directors comprises two types of representatives: Newron Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Newron. The board's role is to monitor Newron Pharmaceuticals' management team and ensure that shareholders' interests are well served. Newron Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Newron Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ravi Anand, Chief Officer | ||
| Roberto Galli, VP Fin | ||
| Stefan Weber, CEO Director | ||
| Marco Caremi, Exec Devel |
Newron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Newron Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.4 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (2.44) % | |||
| Operating Margin | (1.84) % | |||
| Current Valuation | 32.84 M | |||
| Shares Outstanding | 17.85 M | |||
| Shares Owned By Insiders | 4.96 % | |||
| Shares Owned By Institutions | 7.28 % | |||
| Price To Earning | (11.88) X | |||
| Price To Book | 7.98 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Newron Stock Analysis
When running Newron Pharmaceuticals' price analysis, check to measure Newron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newron Pharmaceuticals is operating at the current time. Most of Newron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.